P/E ratio for Sangamo Therapeutics (SGMO)
P/E ratio as of April 2024 (TTM): -0.3369
According to Sangamo Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.336875. At the end of 2022 the company had a P/E ratio of -2.51.
P/E ratio history for Sangamo Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.51 | -58.47% |
| 2021 | -6.05 | -63.97% |
| 2020 | -16.8 | 74.47% |
| 2019 | -9.62 | -40.5% |
| 2018 | -16.2 | -30.99% |
| 2017 | -23.4 | 683.51% |
| 2016 | -2.99 | -81% |
| 2015 | -15.7 | -59.64% |
| 2014 | -39.0 | 31.97% |
| 2013 | -29.6 | 111.45% |
| 2012 | -14.0 | 249.42% |
| 2011 | -4.00 | -66.87% |
| 2010 | -12.1 | -8.23% |
| 2009 | -13.2 | 126.82% |
| 2008 | -5.80 | -74.16% |
| 2007 | -22.4 | 87.07% |
| 2006 | -12.0 | 48.88% |
| 2005 | -8.06 | -26.12% |
| 2004 | -10.9 | -16.24% |
| 2003 | -13.0 | 423.55% |
| 2002 | -2.49 | -72.03% |
| 2001 | -8.90 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -3,171.47% | 🇺🇸 USA |
 Amgen AMGN | 18.6 | -5,612.10% | 🇺🇸 USA |
 Biogen BIIB | 10.3 | -3,163.66% | 🇺🇸 USA |
 Dow DOW | 30.7 | -9,213.50% | 🇺🇸 USA |
 Gilead Sciences GILD | 15.1 | -4,573.65% | 🇺🇸 USA |
 Merck MRK | 68.7 | -20,506.44% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -35.3 | 10,384.22% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 116 | -34,437.07% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.